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Dosimetry Calculations of Radiopharmaceuticals
Abstract
The goal of this project is to determine the absorbed dose of radiation to a patient using 99mTc-MAA as a
tracer for a lung scan using the MIRD formula accounting only for the radiation dose contributed by the
target organ. The radiation dose for other organs to the target organ is considered negligible as the
uptake of 99mTc-MAA from other organs is less than 1%. In addition to calculating the absorbed dose of
radiation, the initial dose rate was also calculated by back solving to determine the total mass of the
lungs. The radiation dose to the patient by the target organ was calculated to be 269.44 mrads and the
initial dose rate was determined to be 156 mrads/hr.
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PROBLEM STATEMENT
Calculate the absorbed dose to the lungs of an adult patient who received
99m

Tc-MAA, assuming

Pertinent data are:

(

)

uptake and uniform distribution of the radioactivity in the lungs.
and

. (Saha 199)

1. Calculate the absorbed dose of radiation from the target organ.
2. Calculate the initial dose rate.

MOTIVATION
The calculation of absorbed radiation is crucial for the safety of both the patient and the
nuclear medical technician. Radiation overdose risks include vomiting, damage to the
hematopoietic system, and death (Saha 199). These risks associated with the stages and dose
ranges are outlined in Table 1 in the Appendix. Radiopharmaceuticals have multiple uses. They
can be used as tracers for Positron Emission Tomography (PET), studies to determine factors
such as certain metabolisms, and absorption and as treatment for certain diseases and conditions.
The problem listed above would be a typical dose to a male patient undergoing a PET scan of the
lungs to detect a pulmonary embolism. However, the hand calculation of radiation dosing has
become essentially obsolete due to the use of computer programs that account for additional
variables that differ from patient to patient.
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MATHEMATICAL DESCRIPTION AND SOLUTION APPROACH
The Medical Internal Radiation Dose (MIRD) formula is an equation that can be used to
determine the dose of radiation to a patient using physical and biological factors such as the
ive half-life, target organ mass, as well as many
other factors determined by the Society of Nuclear Medicine. The effective half-life
99m

of the

Tc source must first be calculated to determine the dose formula. This is done by considering

that the effective decay constant is given by

, where

and

are the physical and

biological decay constants respectively. Since any decay-constant is equal to the factor

times

the reciprocal of the half-life, the effective decay constant formula may be rewritten as
.
The physical half-life of 99mTc is
source is

and the proposed biological half-life of the 99mTc
for the 99mTc source of

. This gives an effective half-life

Next, the dose rate is given in units of

(1)

.

as
,

where
the value

is the absorbed fraction of radiation from the source organ

(2)
to the target organ

is a conversion factor so that equation (2) is will be expressed in

the equilibrium dose is given by

and

. Since

equation (2) becomes
.

(3)

Due to physical and biological decay of the radioactivity , the dose rate will decrease
accordingly. Supposing that
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,
where

(4)

is the radioactivity in the target organ. To obtain the dose of radiation absorbed,

equation (4) is integrated over the interval

giving
.

(5)

Because the effective decay constant is related to the effective half-life by

,

equation (5) becomes
.
The sum of all the products of the equilibrium dose

(6)

and the absorbed fraction

is takes into

account the multiple types of radiation that a radionuclide may give off. Thus total radiation dose
is expressed as
.

(7)

Results for the major radiation types that 99mTc releases can be found in Table 2. After the sum
has been determined,

can be substituted for

, and

for

, finally giving

.
The values of

and

(8)
yield a dose of

.

Now the mass of the lungs must be found to determine the dose rate. This is done by
using the calculations of Table 2 in the Appendix and exploiting the fact that
, i.e.,
dose rate is determined to be

https://digitalcommons.usf.edu/ujmm/vol3/iss1/19
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DISCUSSION
The MIRD formula has improved the accuracy of dosimetry calculations by reducing the
number of assumptions needed to perform dosimetry calculations as opposed to the classic
method of dosimetry (Early 90). However, the MIRD formula has proved to be limited by other
factors. One of these limitations is the
coefficient of variation of

or greater represents a considerable uncertainty in the estimate of

(Early 90). Other limitations include biological calculation factors such as
the kidney model not being divided into cortex and medulla, the bladder and stomach being a
fixed size, (Early 90) and the fact that the MIRD formula presupposes that the source is
uniformly distributed within a standard(Early 92). It is imperative that these factors are taken into account, and that the dosimetrist be
knowledgeable of the assumptions and limitations (Early 92). With the invention of more
powerful computers and additional formulas to take limitations such as the coefficient of
variation, organ size and shape, and the uniform distribution of the radionuclide dosimetry,
calculations have become far more accurate than the MIRD formula used in this project.

CONCLUSION AND RECOMMENDATIONS
The project was successful in the calculation of the absorbed dose of radiation from the
target organ and the initial dose rate. The calculated dose of radiation was
the calculated initial dose rate was

and

. This problem however, does not account for

other dose contributions from other source organs to the target organ, and only accounts for the
dose contribution of the target organ to itself. These additional dose contributions would have
proved negligible as the remaining
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in which 99mTc-MAA implants. These organs would have included the kidneys, liver, ovaries or
testes, and the whole body. Although negligible in this project, future projects could account for
these additional dose contributions from organs other than the target organ.

NOMENCLATURE
Symbol

Description

Value/Unit

Time
Effective half-life
Physical half-life
Biological half-life
Radioactivity
Radioactivity in target organ

Mass of target organ
Fraction of quanta emitted per disintegration for the
th radiation
Energy of the emitted quanta for the th radiation
Absorbed Fraction from source organ ( ) to target
organ ( ) for the th radiation
Equilibrium Dose for the th radiation
Effective decay constant
Cumulative radiation dose for the th radiation
Total radiation dose

https://digitalcommons.usf.edu/ujmm/vol3/iss1/19
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Symbol

Name / Unit

Conversion

Curie / Radioactivity
Becquerel /
Radioactivity
Million electron volts /
Energy
Rad / Energy
Gray / Energy
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APPENDIX: TABLES
Dose Range

Stage

Symptoms

1

0-200 (0-2)

Usually unobservable

2

150-400 (1.5-4)

Transient nausea and vomiting; some
evidence of damage to hematopoietic
system, recovering in 1 to 2 months

3

350-600 (3.5-6)

Severe damage to hematopoietic
system; bone marrow transplant
essential; survival chances, moderate

4

550-1000 (5.5-10)

Gastrointestinal damage; severe
nausea, vomiting and diarrhea; very
small chance of recovery; death
follows in 10-24 days

5

1000 and above (10 and higher)

Confusion, shock, burning sensation;
death follows within hours

Table 1: Stages of radiation overdose with corresponding dose ranges and symptoms from
Ref. (Early).

Radiation
photon
X rays (

)

Electrons
Total

:

Table 2: Major forms of radiation associated with 99mTc-MAA and their
associated equilibrium dose and absorbed fraction from Ref. (Saha).
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